about
sameAs
The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines.HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathwayThe Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequenceModulation of human immunodeficiency virus 1 replication by interferon regulatory factorsGuanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseasesBiocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccinesHIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic regionTherapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTBuilding collaborative networks for HIV/AIDS vaccine development: the AVIP experience.HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Identification of recent HIV infections and of factors associated with virus acquisition among pregnant women in 2004 and 2006 in Swaziland.Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function.Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells.Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice.Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma.The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyAn attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challengeImpact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6PCytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma.Challenges in HIV Vaccine Research for Treatment and Prevention.Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.Angiogenic properties of human immunodeficiency virus type 1 Tat proteinHuman herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis.HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesHIV-1 Tat-based vaccines: from basic science to clinical trials.Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids.Treatment of Kaposi's sarcoma--an update.The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.Effect of MHC haplotype on immune response upon experimental SHIVSF162P4cy infection of Mauritian cynomolgus macaquesMolecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms.Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialOn the role of interferon regulatory factors in HIV-1 replication.A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rheAntitumour effects of antiretroviral therapy.HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancerProblems and emerging approaches in HIV/AIDS vaccine development.
P50
Q24534479-6FECC753-C7A9-46D7-8532-A0F2F329C1C7Q24541552-E10D68D3-1560-4DBB-A458-E64967F37F7BQ24561727-B58A2095-CD59-4494-81F1-BEB357FFF818Q24674143-EAE1B099-0488-4BBE-96B1-C2596F9E634EQ24685277-D66B4396-0912-41AA-B9E0-AC460DBE7147Q27333734-32E8E3A3-E583-41EC-9920-F0CDBA88DEABQ28252310-53CA66B3-94D1-4F28-8AFB-6CC2525B9844Q28476094-24E209D2-1715-4019-84F8-EAD413D898B8Q30356937-9AC00992-EAF3-42DD-95C5-F8478D35D5F4Q30381447-A87D5B0E-B91F-412C-B9EA-A06480DDEDFDQ30390213-E3FEAFD1-89D3-4EF4-B736-B52E77302AEAQ31886420-6A98929C-5E12-4E51-958A-CB71973BEFB3Q33684710-D5BB146B-EC8B-446A-B3D8-5F394B3316A0Q33739129-330A64FC-DCB5-45C0-9E76-7BE90C9156A1Q33844645-10EC79B1-59C8-4E0C-961B-A120D05F64FCQ33864926-1DF51A93-D5F1-4F94-95DC-1CC344C0990DQ33916162-A424E27C-A5B2-43BD-96CC-61481CBC5BEBQ34055475-8AE1A845-060D-4381-A57D-74ACCE9CD4E8Q34095553-D036FE98-87B1-4328-84BE-3E8E9076C864Q34148683-11DEF877-6E0B-4B7D-B950-B7B63481625DQ34209585-D3957E30-8ABD-4B2F-848C-B602242B24EFQ34267637-77C08C9B-2D1F-49BA-962E-2F0C0BFCFED5Q34295801-D1F853C8-52BF-4C2D-9322-66BC00396B1FQ34477471-D4A7520E-2569-43C5-B35B-9F8226B59CE1Q34978901-3527776B-8A74-4A40-80EA-BD746F83C867Q34988603-267C5270-2E0A-481C-B9EA-0AC0E523A3D1Q35002125-2D353A99-0728-4E86-B6F3-199980FE72B0Q35040673-4C02E451-DDEE-476A-9569-92D42F07786FQ35058310-4638E5D2-961C-4AE6-975E-A9142DBF6ADDQ35138516-1794D26F-B0A6-42FC-99AA-7E920CBCC63BQ35161426-DFEA4789-FFE8-4CBC-BC1C-966597D53DB4Q35215799-8F2EEFA2-CA9B-4638-8B86-E45DE234BB56Q35294664-6940FD40-79E7-4097-A7A4-571D99E343D1Q35552889-53D2AD5B-F370-4D82-992B-6312DFBE31AAQ35700273-1F0C187A-743A-4769-AE63-70F96FD489A0Q35785031-5CAEF526-942C-416B-9A62-5A4ACFDACC5DQ35934144-B16938FD-5525-403D-BF78-B403B05CD4EBQ36109585-9C0F8F76-CE33-49CA-8E74-D8B7CAC70ACCQ36498248-C1D2D491-A1EF-4FC7-9611-6D94BF248A43Q36758574-7B82DFA3-04DF-43BD-B422-8253CCAA465E
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Barbara Ensoli
@ast
Barbara Ensoli
@de
Barbara Ensoli
@en
Barbara Ensoli
@es
Barbara Ensoli
@nl
Barbara Ensoli
@sl
type
label
Barbara Ensoli
@ast
Barbara Ensoli
@de
Barbara Ensoli
@en
Barbara Ensoli
@es
Barbara Ensoli
@nl
Barbara Ensoli
@sl
prefLabel
Barbara Ensoli
@ast
Barbara Ensoli
@de
Barbara Ensoli
@en
Barbara Ensoli
@es
Barbara Ensoli
@nl
Barbara Ensoli
@sl
P214
P1053
J-9169-2016
P106
P2080
P21
P214
P31
P3829
P396
IT\ICCU\SNTV\000498
P496
0000-0002-0545-8737
P569
1960-01-01T00:00:00Z
2000-01-01T00:00:00Z
P735
P7859
lccn-n2003127534